DE69734387D1 - Ein kombiniertes antigen vom menschlichen cytomegalievirus und seine anwendung - Google Patents

Ein kombiniertes antigen vom menschlichen cytomegalievirus und seine anwendung

Info

Publication number
DE69734387D1
DE69734387D1 DE69734387T DE69734387T DE69734387D1 DE 69734387 D1 DE69734387 D1 DE 69734387D1 DE 69734387 T DE69734387 T DE 69734387T DE 69734387 T DE69734387 T DE 69734387T DE 69734387 D1 DE69734387 D1 DE 69734387D1
Authority
DE
Germany
Prior art keywords
hcmv
human
cytomegalievirus
application
combined antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69734387T
Other languages
English (en)
Other versions
DE69734387T2 (de
Inventor
Anna Bruggeman
Cornelis Vink
Frans Stals
Albert Ramon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUBIO PRODUCTS BV, MAASTRICHT, NL
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Application granted granted Critical
Publication of DE69734387D1 publication Critical patent/DE69734387D1/de
Publication of DE69734387T2 publication Critical patent/DE69734387T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69734387T 1996-02-22 1997-02-20 Ein kombiniertes antigen vom menschlichen cytomegalievirus und seine anwendung Expired - Lifetime DE69734387T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/605,541 US5800981A (en) 1996-02-22 1996-02-22 Human cytomegalovirus antigen and its use
US605541 1996-02-22
PCT/EP1997/000865 WO1997031117A2 (en) 1996-02-22 1997-02-20 A human cytomegalovirus combined antigen and its use

Publications (2)

Publication Number Publication Date
DE69734387D1 true DE69734387D1 (de) 2006-03-02
DE69734387T2 DE69734387T2 (de) 2006-07-06

Family

ID=24424094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69734387T Expired - Lifetime DE69734387T2 (de) 1996-02-22 1997-02-20 Ein kombiniertes antigen vom menschlichen cytomegalievirus und seine anwendung

Country Status (9)

Country Link
US (1) US5800981A (de)
EP (1) EP0882132B1 (de)
JP (1) JP2001517072A (de)
AT (1) ATE307207T1 (de)
AU (1) AU732254B2 (de)
DE (1) DE69734387T2 (de)
DK (1) DK0882132T3 (de)
ES (1) ES2251016T3 (de)
WO (1) WO1997031117A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
EP1057895A1 (de) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
US6569616B1 (en) * 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
CA2756797C (en) * 2002-12-23 2015-05-05 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004076645A2 (en) * 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
WO2007036056A1 (en) * 2005-09-27 2007-04-05 Oncalis Ag Genetic selection system to identify proteases, protease substrates and protease inhibitors
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CA3022196A1 (en) 2008-07-16 2010-01-21 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2516463B1 (de) 2009-12-23 2016-06-15 4-Antibody AG Bindeelemente für menschliches cytomegalovirus
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1266740B1 (it) * 1994-07-01 1997-01-14 Maria Paola Landini Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
DE4426453C1 (de) * 1994-07-26 1995-11-02 Biotest Ag Rekombinant hergestellte Fusionsproteine des Cytomegalievirus und diese enthaltende diagnostische Testkits

Also Published As

Publication number Publication date
DK0882132T3 (da) 2006-03-06
WO1997031117A3 (en) 1997-10-02
ATE307207T1 (de) 2005-11-15
US5800981A (en) 1998-09-01
ES2251016T3 (es) 2006-04-16
DE69734387T2 (de) 2006-07-06
JP2001517072A (ja) 2001-10-02
AU732254B2 (en) 2001-04-12
EP0882132B1 (de) 2005-10-19
WO1997031117A2 (en) 1997-08-28
AU1876397A (en) 1997-09-10
EP0882132A2 (de) 1998-12-09

Similar Documents

Publication Publication Date Title
DE69734387D1 (de) Ein kombiniertes antigen vom menschlichen cytomegalievirus und seine anwendung
WO2003048337A3 (en) Antibody to latent membrane proteins and uses thereof
NO991449D0 (no) Antistoff mot human parathormon-relaterte peptider
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69703813D1 (de) System zur expression von heterologen antigenen als fusionsproteine
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
AU1866895A (en) Human monoclonal antibodies to herpes simplex virus and methods therefor
EP0344940A3 (de) Antikörper gegen latente Proteine von menschlichen Papillomavirus, diagnostische Systeme und Methoden
AU2573595A (en) Antibodies which bind to insect gut proteins and their use
AU8172094A (en) Synthetic HTLV-III peptides, compositions and uses thereof
FI910497A0 (fi) Nytt virus vid infektioes bursalsjukdom.
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
HUP9801223A3 (en) Method for enhancing the antibody response to specific antigens with interleukin-10
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE59209942D1 (de) HCMV-spezifische Peptide und ihre Verwendung
DK364286A (da) Varicella-zoster virus (vzv) ga, gb og gc glycoproteiner i renset, ikke-denatureret, serologisk aktiv form og fremgangsmaade til proevning for tilstedevaerelsen af antistoffer over for disse
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
CA2270408A1 (en) Monoclonal antibodies against the ypydvpdya epitope, process for producing the same and their use
CA2246802A1 (en) A human cytomegalovirus combined antigen and its use
NO883603D0 (no) Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel.
ATE189897T1 (de) Antikörper gegen das prorenin profragment, reninaktive substanz die diese enthält und prorenintest die diese verwendet
FI954827A0 (fi) Monoklonaalisia anti-CD4-vasta-aineita kantavia immuunipartikkeleita ja niiden käyttö
KR950702244A (ko) 백신으로서의 즉석 초기 hsv-2 비루스 단백질 icp27(immediatie early hsv-2 viral protein icp27 as vaccine)
FR2737209B1 (fr) Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MUBIO PRODUCTS BV, MAASTRICHT, NL

8328 Change in the person/name/address of the agent

Representative=s name: MUELLER FOTTNER STEINECKE RECHTSANWAELTE PATENTANW